enVVeno Medical Corporation reported a cash burn of $3.8 million for the second quarter of 2025, which remained in line with its projected quarterly range. The company confirmed that its cash and investments are sufficient to fund operations through Q3 2026 at the current cash burn rate, providing a solid financial runway.
Commercial readiness activities are underway for a phased launch of the VenoValve, contingent upon an FDA decision expected in the second half of 2025. This indicates the company is preparing for market entry while awaiting regulatory clearance.
The Investigational Device Exemption (IDE) submission for enVVe remains on track for the second half of 2025, indicating continued progress on its next-generation device. This dual-product strategy aims to address a broad spectrum of deep venous CVI patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.